FDA approves CAMZYOS for pediatric obstructive cardiomyopathy
AI Summary
The U.S. FDA approved CAMZYOS for pediatric obstructive cardiomyopathy. The decision expands the drug’s labeled use into a younger patient population.
Related Articles
COP31 targets 35% global electrification by 2035
Punch Nigeria —
Ukrainian drones strike major Russian Baltic export port
Splash247 Maritime —
NYSHEX raises US$8.7 million to expand NYFI freight index
Container News —
Hapag’s standalone Asia-Mexico string adds another spoke to Gemini hub network
The Loadstar —
Fate of Perth’s David Jones stores revealed amid retailer’s ‘urgent restructure’
The Sydney Morning Herald —
China’s Singles Day shopping festival puts AI selling power to the test
The Straits Times —